Fierce Biotech July 12, 2024
Annalee Armstrong, Darren Incorvaia

Welcome to this week’s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Gabrielle Masson and it will be featured here at the end of each week.

Veteran Pfizer R&D leader takes a bow

After leading Pfizer’s R&D unit through the pandemic, Chief Scientific Officer Mikael Dolsten, M.D., Ph.D., is heading out.

The New York pharma giant announced the departure Tuesday, at the same time launching a public search for a successor.

“I want to thank Mikael for his incredible contributions, not only to Pfizer and the scientific community but to the millions of patients he has impacted over the years. Mikael is a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
New 'how-to guide' for future rapid vaccine development
Infographic: R&D Spending Growth of Top Pharma Companies
Medicare prescription drug pricing variance: 5 things to know
Payer group 'deeply concerned' by Medicare weight loss drug coverage proposal
Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Share This Article